{
  "docId": "019dd923-5de0-76bd-a169-83187257f35b",
  "docSlug": "5d146414b5cc38c9",
  "documentTitle": "Vaccines & Therapeutics Outlook Part I: Timelines and Success Factors",
  "authorId": "BCG",
  "authorName": "BCG",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 16,
  "pageCount": 34,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "initiative_list",
  "function": "prioritize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a quote from Dr. Peter Marks regarding herd immunity and vaccine efficacy.",
  "elementsJson": [
    "headline_text",
    "numbered_list",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5de0-76bd-a169-83187257f35b/16",
  "deckHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b",
  "deckJsonHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b.json",
  "deckAnchorHref": "/decks/019dd923-5de0-76bd-a169-83187257f35b#slide-16",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Immediate priorities that emerge basis vaccine efficacy outcomes",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad96-dcd22e4a4360",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.33,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. Ensuring consistent communication for adoption & continued implementation of non-pharmaceutical interventions (NPIs) like masks, social distancing, etc. 2. Continued impetus for development of alternative (higher efficacy) vaccines and therapeutics, and rapid testing technologies 3. Sustaining demand generation in appropriate population segments; and investing to maximize public health benefit",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2115d464-cc96-4374-895f-b975170cdf31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.33,
        "y": 0.62
      },
      "kind": "list",
      "text": "1. Maintaining sufficient supply and resources for broad administration to meet initial surge in demand 2. Building a tiered distribution strategy to prioritize vulnerable and impacted populations in a supply constrained scenario 3. Continued consistent communication to ensure adoption across population segments and keeping skeptics at bay",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c60cba23-1f4a-4e7c-b282-5f89dcaa0451",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "quote",
      "text": "\"...if you had 70, 80 percent efficacy and enough of the population is vaccinated with it, COVID-19 will have nowhere to go, and it will just go away. That's what happened for smallpox. It's what happened for measles, with the exception of the occasional times we've had re-importation.\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4ab9976-ed5b-4dd0-a96d-09d8e8cc242c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"...if you had 70, 80 percent efficacy and enough of the population is vaccinated with it, COVID-19 will have nowhere to go, and it will just go away. That's what happened for smallpox. It's what happened for measles, with the exception of the occasional times we've had re-importation.\" Dr. Peter Marks, Director FDA CBER",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-fefb-728e-ad96-e30f124ca61c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.33,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. FDA CBER: FDA Center for Biologics Evaluation and Research. Source: FDA, BCG",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3ac7be3-193c-4287-8d17-6ebf61376863",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Vaccine efficacy expected to impact demand dynamics & healthcare response priorities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4194c43-a93a-482a-9ff5-c81c02933c9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.33,
        "y": 0.14
      },
      "kind": "title",
      "text": "Immediate priorities that emerge basis vaccine efficacy outcomes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7d66de8-a40f-435c-babe-0888795fa436",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-163f-72bd-8a09-4c25cc3f28e9",
      "evidence": "Title links efficacy -> demand dynamics + healthcare priorities.",
      "confidence": 78
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "019dd95a-0702-74a3-87e3-afd1671a9591",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Vaccines/therapeutics as path; timelines, fast movers, success factors",
      "position": 3,
      "confidence": 78,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 19,
      "from": 15,
      "beatId": "019dd95a-0702-74a3-87e3-bed022269a97",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Implications (So What)",
      "beatSlug": "triple-take-the-implications-so-what",
      "evidence": "Key success factors, efficacy priorities, scenarios",
      "position": 2,
      "confidence": 65,
      "parentBeatName": "Reflection",
      "parentBeatSlug": "reflection"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 15,
      "name": "So What Cascade",
      "slug": "41-so-what-cascade",
      "bestFor": "Data presentations, executive summaries, driving to recommendations",
      "matchId": "019dd95a-088c-724c-b30f-c34ed2dbf344",
      "evidence": "p15 lists efficacy/safety/immunity factors; p16 cascades into immediate priorities by efficacy band.",
      "position": 4,
      "objective": "Translate three vaccine success factors into priority actions by efficacy outcome",
      "structure": "The Data -> So What? (Insight 1) -> So What? (Insight 2) -> So What? (The Action)",
      "confidence": 78,
      "description": "Chain insights together, each answering 'so what?' until you reach the actionable conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}